The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Shanghai Simnova Biotechnology

Status and phase

Enrolling

Phase 1

Conditions

Recurrent Glioblastoma Multiforme

Treatments

Drug: SNC-109 CAR-T Cells

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05868083

SNC-109-101

Details and patient eligibility

About

This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.

Full description

It is planned to recruit about 16 patients with rGBM subjects. The protocol consists of screening period, Lymphocytes apheresis period, Operation period, pre-infusion evaluation (-2~-1 days), infusion (day 0), infusion observation (day 1-post infusion), and follow-up period (last infusion-720 days). The incidence of dose limitation toxicity (DLT) will be observed within 28 days after the first infusion. Subjects in this study will receive multiple infusions, starting with 2×104 CAR+ T cells/dose in the first subject, and the Safety Review Committee (SRC) will evaluate the subsequent dosing regimen, dose, infusion interval, and number of treatment cycles. Subsequent subjects will be evaluated by the SRC on the basis of available PK and safety data, and the SRC will determine the dosing regimen, dose, infusion interval and number of treatment cycles based on observed evidences.

Enrollment

16 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 and ≤70，both sexes;
Diagnosed with a history of glioblastoma, and the recurrent glioblastoma has confirmed by histological/molecular pathology (including astrocytoma World Health Organization (WHO) Grade 4);
Karnofsky (KPS) ≥60;
The estimated survival time is ≥8 weeks;
Blood pregnancy tests for women of childbearing age are negative;
The patient himself/herself, and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form.

Exclusion criteria

Known allergies to study drugs or drugs that may be used in the study;
Severe concurrent diseases in the heart, lungs, liver, or other vital organs;
Hypertension is poorly controlled or accompanied by hypertensive crisis or hypertensive encephalopathy;
In addition to the glioblastoma, with other severe central nervous system diseases or complications or aggressive malignancies;
Long-term use of immunosuppressant drugs, or large doses of steroids;
Received live or attenuated vaccine or other surgery had no related to GBM within 4 weeks prior to Lymphocytes apheresis;
Lymphocytes apheresis or cell infusion combined with infection or unexplained fever.